The ENRICH study examined BRII-179 as a priming therapy before administering elebsiran and PEG-IFNα.
Brii Bio announces positive end-of-treatment results from phase 2b ENRICH & ENHANCE studies to treat chronic hepatitis B: Durham, North Carolina Monday, July 6, 2026, 18:00 Hrs [I ...
ITU AI for Good Global Summit 2026 opens Day Zero on July 7 at Palexpo Geneva, featuring agentic AI security workshops and ...
Radiation therapy remains a central modality in cancer treatment, but normal-tissue toxicity and long-term stochastic effects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results